- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Injection containing lipegfilgrastim.
This product has been produced by recombinant DNA technology using E.coli.
Reduced duration of neutropenia
Reduced incidence of febrile neutropenia
One 6mg dose of lipegfilgrastim is recommended 24 hours after each chemotherapy cycle.
Children under 18 years
Chronic myeloid leukaemia
Hereditary fructose intolerance
Secondary acute myeloid leukaemia
Precautions and Warnings
History of pulmonary infiltrates
Recent history of pneumonia
Sickle cell disease
Incidence of thrombocytopenia and anaemia not reduced by treatment
Treatment to be initiated and supervised by a specialist
Presentations with sorbitol unsuitable in hereditary fructose intolerance
For single use only
Record name and batch number of administered product
Monitor full blood count and differential WBC before and during therapy
Consider splenic rupture if patient has abdominal or shoulder pain
Monitor for symptoms of Capillary Leak Syndrome
Monitor haematocrit values
Monitor patients with sickle cell anaemia
Monitor serum potassium regularly
Monitor spleen size
Perform regular urinalysis
Advise patient to seek medical advice if signs/symptoms of aortitis occur
Antibodies to ingredient may develop
Seek urgent medical attention if symptoms of Capillary Leak Syndrome occur
May affect bone imaging results
Discontinue if adult respiratory distress syndrome occurs
Discontinue if leucocyte count exceeds 50x10 to the power of 9/L
Discontinue if serious allergic or anaphylactic reaction occurs
Discontinue or reduce dose if glomerulonephritis occurs
Concurrent cytotoxic drugs: Maintain established dose regime (no increase)
If aortitis is suspected it can usually be diagnosed by CT scan and generally resolves after withdrawal of lipegfilgrastim.
Pregnancy and Lactation
Lipegfilgrastim is contraindicated during pregnancy.
The manufacturer recommends lipegfilgrastim is not used during pregnancy.
There are very limited data on the use of lipegfilgrastim in pregnant women. Animals studies have shown reproductive toxicity.
Lipegfilgrastim is contraindicated during breastfeeding.
The manufacturer recommends that breastfeeding should be discontinued during treatment with lipegfilgrastim.
It is not known whether lipegfilgrastim and its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded.
Acute febrile dermatosis (Sweet's syndrome)
Adult respiratory distress syndrome
Capillary leak syndrome
Increase in alkaline phosphatase
Increase in lactate dehydrogenase
Local pain (injection site)
Local reaction at injection site
Raised neutrophil count
Sickle cell crisis
Effects on Laboratory Tests
Positive bone imaging findings have been associated with growth factor therapy due to the increase in haematopoietic activity in the bone marrow. This effect should be considered when bone-images are taken.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: September 2019
Summary of Product Characteristics: Lonquex 6mg solution for injection. Teva Pharma B.V. Revised July 2019.
HPRA Drug Safety Update June 2018 Edition 88
Available at: https://www.hpra.ie/homepage/about-us/publications-forms/newsletters
Last accessed: 17 September 2019
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.